58-WEEK OPEN-LABEL TRIAL OF TAVAPADON IN PARKINSONS DISEASE (TEMPO-4 TRIAL)
Enrolling By Invitation
40 years - 80 years
All
Phase
3
800 participants needed
1 Location
Brief description of study
The research study is being conducted to study of an investigational drug (referred to as “study drug” in this document) called CVL-751 (also known as Tavapadon) as a possible treatment for Parkinson’s disease. An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Parkinsons Disease
-
Age: 40 years - 80 years
-
Gender: All
Previous TEMPO-1 trial participants and diagnosed with Parkinson’s Disease
Updated on
04 Aug 2024.
Study ID: 849393
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
